Pharmacy Prior Authorization

AETNA BETTER HEALTH ILLINOIS (MEDICAID)

Aranesp (Medicaid)

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to Aetna Better Health Illinois at **1-855-684-5250**.

When conditions are met, we will authorize the coverage of Aranesp (Medicaid).

Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise.

Drug Name (please circle)			
Aranesp (darbepoetin alfa)			
Other, please specify			_
Quantity	Frequency Stren	ngth	_
Route of Administration	Expected Length of therapy		
Patient ID: Patient Group No.: Patient DOB: Patient Phone:			
Prescribing Physician			
Physician Name:			
Specialty:	NPI Number:		
Physician Fax:	Physician Phone:		
Physician Address:	City, State, Zip:		
Diagnosis:	ICD Code:		
Please circle the appropriate answer for each	ch question.		
previous authorization is on file	edication in the past for this patient (i.e., under this plan)?	Y	N
[If yes, skip to question 10.]			
evidenced by one of the following equal to 100 ng/ml and transferri	e iron stores to support erythropoiesis as ag: A) Serum ferritin greater than or n saturation (iron saturation) greater mal serum iron, TIBC and serum ferritin, content (CHr) greater than 29	Y	N
Please document Iron Studies o	btained, results, and date drawn:		

Reference Number: C4911-A / Effective Date: 06/16/2017

	[If no, then no further questions.]		
3.	Does the patient have uncontrolled high blood pressure?	Υ	N
	[If yes, then no further questions.]		
4.	Does the patient have a diagnosis of anemia due to chronic kidney disease?	Υ	N
	[If no, skip to question 6.]		
5.	Does the patient have hemoglobin less than 10 g/dL within 2 weeks prior to initiating therapy?	Υ	N
	Please document hemoglobin and date drawn:		
	[If no, then no further questions.]		
	[If yes, skip to question 9.]		
6.	Is therapy requested for the treatment of anemia in a cancer patient?	Υ	N
	[If no, then no further questions.]		
7.	Is the patient currently receiving chemotherapy?	Υ	N
	[If no, then no further questions.]		
8.	Does the patient meet all of the following conditions for approval: A) Hemoglobin less than 10 g/dL within the 2 weeks prior to starting therapy, B) Diagnosis of non-myeloid malignancy (e.g., solid tumor), and C) Patient will receive chemotherapy for at least 2 additional months	Υ	N
	Please document hemoglobin and date drawn:		
	[If no, no further questions.]		
9.	Has the patient experienced treatment failure or intolerable side effects with Epogen and Procrit?	Υ	N
	[No further questions.]		
10	. Does the patient have hemoglobin less than 11 g/dL within the last 2 weeks?	Υ	N
	Please document hemoglobin and date drawn:		
	[If no, no further questions.]		

Reference Number: C4911-A / Effective Date: 06/16/2017

Prescriber (Or Authorized) Signature Da	te	
I affirm that the information given on this form is true and accurate as of this date.		
Comments:		
[No further questions.]		
Please document Iron Studies obtained, results, and date drawn:		
11. Does the patient have adequate iron stores to support erythropoiesis (e.g., serum ferritin above 100ng/mL, transferrin saturation above 20%)?	Y	N

Reference Number: C4911-A / Effective Date: 06/16/2017